The promising field of cell therapy relies on the researchers' ability to carefully engineer a patient's cells using complex combinations of nucleic acids and proteins. As a therapy progresses from concept to clinic, the volume of engineered cells required for successful passage increases dramatically. Therapeutic development is often a race against time, but for many transfection technologies, scaling up can be problematic, causing significant increases in timelines, costs and risks.